%0 Journal Article
%T Management of anlotinibİ\related adverse events in patients with advanced nonİ\small cell lung cancer: Experiences in ALTERİ\0303
%A Baohui Han
%A Faguang Jin
%A Hanping Wang
%A Jianhua Shi
%A Kai Li
%A Kejun Nan
%A Li Zhang
%A Mengzhao Wang
%A Qiming Wang
%A Weiqiang Chen
%A Xiaotong Zhang
%A Xiaoyan Si
%A Xiuwen Wang
%A Yi Luo
%A Ying Cheng
%A Yuankai Shi
%A Zhehai Wang
%J Archive of "Thoracic Cancer".
%D 2019
%R 10.1111/1759-7714.12977
%X Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, plateletİ\derived growth factor receptor, and stem cell factor receptor (cİ\Kit). In the phase III ALTERİ\0303 trial (Clinical Trial Registry ID: {"type":"clinical-trial","attrs":{"text":"NCT 02388919","term_id":"NCT02388919"}}NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced nonİ\small cell lung cancer patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial
%K Adverse event
%K anlotinib
%K multiİ\target tyrosine kinase inhibitor
%K nonİ\small cell lung cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397894/